By Fineline Cube 
Gilead Sciences Inc. (NASDAQ: GILD) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with pembrolizumab (Keytruda) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | EMA/CHMP (European Union) |
| Opinion Type | Positive, recommending marketing authorization |
| Product | Trodelvy (sacituzumab govitecan-hziy) + pembrolizumab (Keytruda) |
| Indication | First-line treatment of unresectable locally advanced or metastatic TNBC in adults who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 (CPS ≥10) |
| Opinion Date | 24 Jul 2026 |
| Next Steps | European Commission review for final marketing authorization decision |
Drug Profile & Mechanism of Action
- Molecule: First-in-class Trop-2-directed antibody-drug conjugate (ADC)
- Target: Trop-2 (trophoblast cell-surface antigen 2) expressed on tumor cells
- Innovation: Delivers SN-38 (topoisomerase I inhibitor) directly to Trop-2-expressing cancer cells while combining with Keytruda’s PD-1 inhibition to enhance anti-tumor immune response
- Current Approvals: Already approved globally for certain patients with metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer
- Combination Rationale: Dual approach targets both tumor cells directly (via ADC) and enhances immune system recognition (via PD-1 blockade)
Clinical Evidence – Supporting Data
| Endpoint | Result (Trodelvy + Keytruda) | Comparator (Standard of Care) | Relative Benefit |
|---|---|---|---|
| Progression-Free Survival | Median 7.2 months | Median 4.9 months | +2.3 months |
| Overall Response Rate | 58% | 32% | +26 ppt |
| Duration of Response | Median 9.1 months | Median 6.3 months | +2.8 months |
| Safety | Manageable toxicity profile; neutropenia (Grade ≥3: 42%), fatigue (Grade ≥3: 8%) | Similar adverse event profile with higher immune-related AEs in combination arm | Consistent with known safety profiles of individual agents |
The pivotal Phase III trial, conducted across North America, Europe, and Asia with >650 patients, demonstrated statistically significant improvement in progression-free survival and overall response rate compared to standard chemotherapy regimens.
Market Impact & Outlook
- TNBC Landscape: Triple-negative breast cancer represents approximately 15% of all breast cancer cases with limited treatment options and poor prognosis
- Patient Population: Estimated 28,000 newly diagnosed metastatic TNBC patients annually in EU5 countries, with ~40% expressing PD-L1 (CPS ≥10)
- Revenue Forecast: Analysts project peak annual sales of €850 million ($920 million) if approved, representing ~12% of Gilead’s current oncology revenue
- Competitive Positioning: Would be the first ADC plus immunotherapy combination approved specifically for first-line PD-L1 positive metastatic TNBC
- Strategic Importance: Strengthens Gilead’s position in the rapidly growing ADC market following its $21 billion acquisition of Immunomedics in 2020
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for Trodelvy. Actual results may differ due to risks including final approval conditions, market adoption, competitive dynamics, and potential changes in treatment guidelines.-Fineline Info & Tech